MIAMI, FL / ACCESSWIRE / March 30, 2016 / Daily Stock Reporter is issuing a report on four stocks to watch. CLSH, YOD, SFOR, and CBIS have been added to our watch list today. Continue reading to find out why. – To get daily alerts on top stocks on the OTC, Nasdaq and NYSE subscribe to our newsletter at DailyStockReporter.com.

CLS Holdings USA, Inc. (OTCQB: CLSH) is a company that focuses on extraction and conversion of cannabinoids. CLS stands for “Cannabis Life Sciences,” acknowledging the company’s patent pending proprietary method of extracting numerous cannabinoids from the cannabis plant and transforming them into a higher quality and quantity of product. In the last 30 days CLSH has seen a price increase of 34.14% from lows of $0.82 in late February to highs in Wednesday’s trading session of $1.10.

Stay Informed and Up To Date On The Hottest Small Cap Nasdaq & OTC Plays. Get Them Here.

YOU On Demand Holdings Inc. (NASDAQ: YOD) is a service provider in China delivering Hollywood movies and premium content to mobile and TV screens, announced Wednesday morning its year-end operating results for the period ended December 31, 2015. The company reported a 135% year-over-year revenue increase. Chairman Bruno Wu added, “We are pleased to have finished 2015 with solid revenue performance, marking the successful completion of a year of both growth and transition. My team has begun steering YOU On Demand in a direction where we can leverage and optimize our current operations as a premium content Video On Demand service provider in China and evolve the brand into a global, mobile-driven, consumer management platform.” The stock saw highs of $2.25 notching in 27.84% gains in Wednesday’s (3/30) trading session.

Enjoy picks like this? Get These Alerts and More on top small cap Companies before They Rally, Text the phrase “StockAlerts” to 635-66.

StrikeForce Technologies Inc. (OTC: SFOR) specializes in Cyber Security solutions for the prevention of Identity Theft and Data Breaches in the last 7 trading days has seen a price hike of 166.66% hitting highs of $0.0008 Wednesday morning from last week’s low of $0.0003. SFOR has seen a significant spike in volume in Wednesday’s (3/30) trading session in comparison to its 3m average volume. The company recently released there updated financial strategy on March 23rd and CEO Mark. L. Kay stated, “StrikeForce’s reinvention is just the beginning of our new strong position in the marketplace. Our management expects, but cannot guarantee, success with our “Out-of-Band” patents and sales. Besides an emphasis on robust sales, we will be focusing on litigation against a number of companies that potentially infringe on our “Out-Of-Band” patents over the next few years, although there can be no assurances of these patents consistently prevailing. Therefore, 2016 is a year we are planning for success for StrikeForce.”

Stay Informed and Up To Date On The Hottest Small Cap Stocks; Free To Join Now.

Cannabis Science Inc. (OTC: CBIS) is a U.S company focusing on the development of cannabis-based medicines announced Wednesday morning that Cannabis Science CEO is excited as record date for gifted shares approaches fast, tomorrow, Thursday, March 31st, 2016, and the new 360,000 sq. ft. facility in Nevada moves into design phase. In the last 7 trading sessions CBIS is up 82.44% bringing in highs in Wednesday’s trading session of $0.0239.

Small Cap Stock Alerts: Get Them straight to your Cell Phone. To Receive Our Winning Small Cap Stock Alerts For Free, text “StockAlerts” to 63566.

ABOUT US:

www.DailyStockReporter.com monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities. Through a vast network of IR professionals www.DailyStockReporter.com is often in the know of several large investor awareness campaigns being deployed.

Timing is everything when trading Penny Stocks. You can subscribe to the www.DailyStockReporter.com newsletter and start receiving daily alerts. To subscribe by phone and receive messages directly to a mobile phone, text the phrase “StockAlerts” to 63566.

Legal Disclaimer

Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements.

EGM FIRM INC which owns www.DailyStockReporter.com, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release.

EGM FIRM INC, which owns www.DailyStockReporter.com, may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice.

EGM FIRM INC which owns www.DailyStockReporter.com, may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two.

CONTACT:

Company: DailyStockReporter.com
Contact Email: news@dailystockreporter.com

SOURCE: DailyStockReporter.com

ReleaseID: 438300

MIAMI, FL / ACCESSWIRE / March 30, 2016 / Top Nasdaq Stocks is issuing a report on four stocks to watch. SUNE, COOL, CRC, and DRWI have been added to our watch list today. Continue reading to find out why. – To get daily alerts on top stocks on the Nasdaq/NYSE subscribe to our newsletter at TopNasdaqStocks.com.

SunEdison, Inc. (NYSE: SUNE) is a solar power company devoted to delivering its clients innovative technology capable of producing renewable clean energy. With thirty locations worldwide, SunEdison is fully capable of supplying clean electricity to home, business, government, and utility-based customers. In the time period from February 24th, to the end of the third trading week in March, March 18th, the stock has increased by 69.05%. The stock has seen an increase of as much as 25.5% on Wednesday 3/30 and volume has begun to trend above its previous averages.

Stay Informed and Up To Date On The Hottest NASDAQ Plays. Get Them Here.

Majesco Entertainment Co. (NASDAQ: COOL) publishes and develops video games for casual fans and families. Majesco creates games for all leading platforms, whether they are a console or a mobile device, and has strong network relationships with retailers nationwide in which their games can be sold. As of the 30th, Majesco’s stock has seen prices as high as 0.99, which is up more than 0.20 from previous monthly lows of 0.72 seen during the month. COOL shares have continued to see increased trading volumes throughout the week, including today (3/30).

Subscribe Now And Reserve A Spot To Receive Our First Alert Of April. Get Your Free Membership Now.

California Resources Corp. (NYSE: CRC) is a California-based oil and natural gas company focused on implementing advanced technology as a means of increasing its production ability. California Resources controls the entire oil process from exploring for, producing, gathering, processing it, and marketing crude oil, natural gas, and natural gas liquids. The stock has had a strong month of March, as the price has increased to as high as $2.20.

Enjoy picks like this? Get These Alerts and More on NASDAQ Companies before They Rally, Text the word “NASDAQ” to 77948.

DragonWave, Inc. (NASDAQ: DRWI) throughout March has seen a move in price of as much as 137% following highs as of the 30th of $4.40. DragonWave is in the business of meeting their customers high-capacity packet microwave needs through the deliverance of solutions that meet their customers need for increasing bandwidth. DragonWave also provides deluxe service and support programs to assure their customers that the company stands firmly behind the products being developed and sold.

Stay Informed and Up To Date On The Hottest NASDAQ Plays. Get Them Here.

About TopNasdaqStocks.com

Looking for stock market and business news headlines? How about up to the minute information on mutual funds and ETFs? Don’t forget about the top stock picks of 2016. TopNasdaqStocks.com has it all. Make sure to subscribe to our free newsletter and to receive free text message alerts on your phone, text “NASDAQ” to 77948.

Disclosure: The information, opinions and analysis contained in this report are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We do not accept any responsibility or liability for any losses, damages or costs arising from an investor’s or other person’s reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities, nor a recommendation of any security. Past gains are not representative of future gains. Pursuant to an agreement between us and a non affiliate 3rd party we were hired for a period beginning on 3/20/16 and ending on 6/19/16 to publicly disseminate information about (cool) including on the website and other media including facebook and twitter. We are being paid $100,000 (cash) for or were paid “zero” shares of unrestricted or restricted common shares. We own zero shares of (cool), which we purchased in the open market. We plan to sell the “zero” shares of (cool) that we hold during the time the website and/or facebook and twitter information recommends that investors or visitors to the website purchase without further notice to you. We may buy or sell additional shares of (cool) in the open market at any time, including before, during or after the website and information, provide public dissemination of favorable information. Top Nasdaq Stocks has not been compensated nor does it expect to receive any compensation for distribution of its opinions and publicly available information regarding CRC, DRWI, or SUNE in this investment opinion article at this time. The opinions contained herein contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. When used herein, the words “anticipate,” “intend,” “estimate,” “believe,” “expect,” “plans,” “should,” “potential,” “forecast,” and variations of such words and similar expressions are intended to identify forward-looking statements. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. A company’s actual results could differ materially from those described in any forward-looking statements contained herein. Top Nasdaq Stocks is not a licensed broker, broker dealer, market maker, investment advisor, analyst or underwriter. We recommend that you use the information found herein as an initial starting point for conducting your own research in order to determine your own personal opinion of the companies discussed herein before deciding whether or not to invest. You should seek such investment, tax, financial, accounting or legal advice appropriate for your particular circumstances. Information about many publicly traded companies and other investor resources can be found at www.sec.gov. Investing in securities is speculative and carries risk. Please visit http://topnasdaqstocks.com/index.php/disclaimer/ website for a more detailed discussion of risks and disclosures.

Contact:

Top Nasdaq Stocks
news@topnasdaqstocks.com

SOURCE: Top Nasdaq Stocks

ReleaseID: 438299

VANCOUVER, BC / ACCESSWIRE / March 30, 2016 / BlackIce Enterprise Risk Management (CSE: BIS) (“BlackIce”) announces the implementation of the Basel II Project utilizing the BlackIce Enterprise Risk Aggregation (ERA™) solution with the Vietnam International Commercial Bank (VIB).

The contract was awarded in October 2015 and BlackIce management have now successfully installed the solution, which includes regulatory and economic capital calculators, regulatory and management reporting, and stress-testing. The implementation was administered together with HPT Vietnam Corporation (HPT) – a local systems integrator, and IBM who supplied their Cognos and Infosphere products. The State Bank of Vietnam (SBV) will soon be announcing their finalized Basel Compliance guidance and as such BlackIce anticipates further business from Vietnamese banks with this success.

Judy Kalyan, BlackIce CEO and Chairman, said “VIB is our first customer to implement ERA in Vietnam and we are delighted that it has been a great success. VIB now has a robust risk-management solution. We will now build on this achievement and look forward to implementing similar solutions based on our ERA platform with other banks who have been eagerly watching the progress of this project. The banking risk arena is becoming increasingly important during 2016 as the State Bank of Vietnam advocates greater compliance from all banks, which provides BlackIce and our partners with a great opportunity”.

BlackIce Enterprise Risk Management Inc. (BlackIce) Enterprise Risk Data Aggregation (ERA) solution gives banking executives supreme confidence in risk decision-making and compliance with a single source for all risk data and a dynamic analytic and reporting platform.

About BlackIce Enterprise Risk Management Inc.
BlackIce is a global enterprise risk management technology firm delivering practical solutions for problems that global banks face every day.

BlackIce has developed an Enterprise Risk Aggregation (ERA™) solution, an open platform software application that delivers end-to-end data and analytical standards to meet all of the regulatory expectations of Basel (I, II & III) as well as the BCBS Risk Data Aggregation & Reporting (RDA) requirements, and the FSB (Financial Stability Board) Legal Entity Identifier program for monitoring concentration risk.

The company’s Governance & Compliance Database (GCD™) is an application that allows financial institutions to assess, govern and manage adherence and compliance to regulatory guidelines across multiple regulatory requirements including: Basel II/III; Living Wills; Risk Data Aggregation and Financial Stability Oversight.

For more information about BlackIce Inc., and ERA™ visit www.blackiceinc.com.

BlackIce Enterprise Risk Management Inc.
Judy Kalyan, Director and CEO

Forward-Looking Information

This press release may include forward-looking information within the meaning of Canadian securities legislation, concerning the business and trading in the common stock of BlackIce Enterprise Risk Management Inc. The forward-looking information is based on certain key expectations and assumptions made by the company’s management. Forward looking statements in this press release include that we expect to sign sales contracts in Vietnam in the near future. The forward looking statements can be affected by competitors’ products, customers determining to delay purchases or not purchase at all, customers not having sufficient funding to purchase, and the possibility of technical or other issues with our software solutions. Orders that are made can be cancelled. Although the company believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because the company can give no assurance that they will prove to be correct. These forward-looking statements are made as of the date of this press release and the company disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.

The CSE has not reviewed, approved or disapproved the content of this press release.

SOURCE: BlackIce Enterprise Risk Management

ReleaseID: 438297

LAS VEGAS, NV / ACCESSWIRE / March 30, 2016 / One major shift we are looking for in healthcare in the coming months is an increased emphasis on bio-electronic medicine, as opposed to pure drug plays. The reason is that the devices currently under development hold the potential to be more effective, with fewer side effects than traditional drug treatments.

One medical technology company we’re keeping a close eye on is; Endonovo Therapeutics, Inc. (OTCQB: ENDV).

Endonovo Therapeutics, Inc. (OTCQB: ENDV) is an innovative biotechnology company developing bioelectronic devices and therapies for regenerative medicine. ENDV‘s technology uses electromagnetic pulses to deliver electrical stimulation to the nervous system and cells. These devices are based on the Time-Varying Electromagnetic Field (TVEMF) technology originally developed at NASA.

ENDV‘s Immunotronics™ platform is a non-invasive, non-implantable bioelectronic device for preventing and treating vital organ failure through the reduction of inflammation and cell death, and the promotion of regeneration.

This technology has been identified in pre-clinical studies to be an innovative approach for treating acute inflammation. The company is targeting inflammatory conditions in vital organs and has set its initial concentration on treating inflammation in the liver. If Endonovo can treat inflammation in vital organs then its technology would be a massive development because most diseases are rooted in inflammation.

Traditionally, medical device companies have largely piggy backed off technologies developed before the FDA regulated medical devices in the 1970’s. This is mainly because they seek to use a much simpler regulatory pathway that many times did not require clinical testing. Approximately 90 percent of yearly FDA reviewed devices are via the 510(k) process, which requires a company demonstrate their device is substantially equivalent to another legally (predicate) marketed device. Meaning, the Company must show it DOES NOT have an innovative technology in order to use this regulatory pathway.

However, this is changing, as a new class of technologies seeks to bring back innovation to the medical device sector. Bio-electronic devices are quickly becoming “the” innovation that will drive the future of medicine, which will use electric pulses to treat diseases and injuries. Bio-electronics have attracted the attention of large pharmaceutical companies, such as GlaxoSmithKline who appears to be extremely bullish on this sector. GSK has bet on the use of bio-electronics to target diseases with the launch of a $50 million venture fund to help develop these innovations.

These innovative technologies have also attracted the help of the Defense Advanced Research Projects Agency (DARPA) and the National Institutes of Health (NIH), who have committed $240 million over six years to encourage researchers to collaborate on these technologies.

Bio-electronic devices, such as ENDV’s can turn the biotech world on its head by replacing billions of dollars of drugs with less expensive and potentially safer devices. The benefits to treating diseases with these devices range from safer treatments, to stronger efficacy.

We like the progress ENDV has made thus far, and believe it is one of the most exciting investments in biotech right now. Given that ENDV is the only publicly traded player in the bioelectronic medicine space that is not a spinal cord/nerve stimulator, it is no wonder that investors are extremely bullish on this small biotech.

Cytori Therapeutics, Inc. (NASDAQ: CYTX) today announced that its U.S. FDA approved Phase III STAR trial has enrolled and treated its 40th patient (50% of target enrollment). In addition, a pre-specified independent data monitoring committee review of safety data from the initial 20 patients has been conducted and the committee has recommended that the study continue as planned. Investors have reacted quite favorably so far.

Athersys, Inc. (NASDAQ: ATHX) Chairman and CEO, Gil Van Bokkelen, presented yesterday at the Alliance for Regenerative Medicine’s 4th Annual Cell & Gene Therapy Investor Day. By all reports the presentation went well and the stock is up thus far. Generally we see stocks going on nice runs after solid presentations.

MannKind Corporation (NASDAQ: MNKD), stock has surged by almost 120% over the past month. Analysts have argued that the run-up has been mostly driven by investors’ excitement over the improved version of Afrezza, a potentially revolutionary diabetes treatment. Hedge funds are beginning to up their positions in this stock, which is an extremely bullish sign.

Celldex Therapeutics (NASDAQ: CLDX) will be presenting seven posters with new clinical and preclinical data at the American Association for Cancer Research (AACR) Annual Meeting 2016 in New Orleans. This could be a massive awareness event for the company. In kind investors seem to be loading shares ahead of the mid April event.

Chimerix, Inc. (NASDAQ: CMRX) Chief Commercial Officer, Linda M. Richardson, presented a week ago at Barclays Global Healthcare Conference at the Loews Miami Beach Hotel in Miami, FL. The presentation could have a positive effect on the stock over the next few sessions. CMRX is a biopharmaceutical company developing novel, oral antivirals to address unmet medical needs.

Put these companies on your radar as well:

Geron Corporation (NASDAQ: GERN), Sangamo Biosciences, Inc. (NASDAQ: SGMO), Esperion Therapeutics, Inc. (NASDAQ: ESPR), PTC Therapeutics, Inc. (NASDAQ: PTCT)

As noted, of these stocks, ENDV is the only one exclusively focused on bringing a bioelectronic device to market. With the market shifting toward companies developing these devices, we believe ENDV requires your immediate attention.

Legal Disclaimer

Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. ACR Communication, LLC. which owns Microcapspeculators.com, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. ACR Communication, LLC., which owns Microcapspeculators.com, may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. ACR Communication LLC., which owns Microcapspeculators.com, may be compensated for its services in the form of cash-based compensation or in equity in the companies it writes about, or a combination of the two. ACR Communication, LLC has been compensated a total of $22,000 cash by a non-affiliate third party of ENDV.

Contact:

Acrlasvegas@gmail.com

SOURCE: ACR Communication, LLC

ReleaseID: 438292

LAS VEGAS, NV / ACCESSWIRE / March 30, 2016 / According to Global Analyst Reports, the combined world market for pancreatic, ovarian and colorectal cancers are expected to reach over $12 billion by 2020.

A company we’re watching closely, Propanc Health Group (PPCH), through its novel PRP treatment, is working toward clinical trials for pancreatic and ovarian cancers, followed by colorectal cancer. The company has also recently discovered indications that it’s treatment could be used on several other forms of tumorous conditions.

Over the past year Propanc has made incredible strides toward achieving this goal, and just recently announced they have received $1.2 million from an institutional investor in order to fast track its preclinical activities, including GMP (Good Manufacturing Practice) manufacturing and preparation for future patient trials, which the Company hopes to file an application for this year.

Since 2007, Propanc, an innovative biopharmaceutical company, has been working with extensive drug development and oncology and clinical experts, Professor Klaus Kutz and Dr. Julian Kenyon whose combined experience of more than 50 years in medicine has been critical in the research and development of PRP anti-cancer treatment.

The experience Propanc’s management has is nothing to gloss over. Klaus Kutz, CMO of Propanc, has prepared multiple investigational new drugs (IND) FDA applications for Sanofi, which is currently trading just under $40 a share; and Dr. Ralph Brandt of Propanc successfully led the tumor biology program for animal studies at Novartis. Novartis is now trading just under $75 a share. Dr Joseph Chalil, a recent addition to the Scientific Advisory Board at Propanc, is a senior executive of Boehringer Ingleheim, one of the world’s 20 leading pharmaceutical companies and a fellow of the American College of Healthcare Executives.

They are on track to adding a success story to their resume with Propanc’s PRP treatment. This would be huge for investors, and judging by recent trading activity, many are loading the boat for this very reason.

With milestones on the horizon such as: a scientific advice meeting with the MHRA (Medicines and Healthcare Products Regulatory Agency), UK, which has been confirmed towards the end of April, followed by a commitment to submit applications for orphan drug designation in the US and EU for pancreatic and ovarian cancers; investors are anticipating some large announcements in the near future and want to be in position to benefit before the secret is out on the enormous potential of PPCH.

PPCH has been on an uptrend over the past few weeks, and that looks to continue, investors should start their research immediately.

Other companies that are listed on major exchanges, and investors should add to their watch list include:

Second Sight Medical Products, Inc. (EYES), Galena Biopharma, Inc.(GALE), Celator Pharmaceuticals (CPXX), Keryx Biopharmaceuticals Inc.(KERX)

Investors are finding tons of opportunity in biotechnology so far in 2016; we think PPCH may just be one of the most exciting of these biotech opportunities. Get yourself in position to earn profits.

Legal Disclaimer

Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. ACR Communication, LLC. which owns Microcapspeculators.com, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. ACR Communication, LLC. which owns, Microcapspeculators.com may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. ACR Communication LLC. which owns Microcapspeculators.com may be compensated for its services in the form of cash-based compensation or in equity in the companies it writes about, or a combination of the two. ACR Communication, LLC. has been compensated $47,000 by Propanc Health Group, Corp. for this news article and for previous as well as future news articles.

Contact:

Acrlasvegas@gmail.com

SOURCE: ACR Communication, LLC

ReleaseID: 438291